Nintedanib in the treatment of systemic rheumatic disease-associated interstitial lung disease

Česká verzia

Authors: Ondřej Zela
Authors place of work: Plicní oddělení Nemocnice ve Frýdku-Místku, p. o.
Published in the journal: Vnitř Lék 2021; 67(6): 330-333
Category: Main Topic

Summary

Systemic rheumatoid diseases form a large group of entities with variable clinical picture and different involvement and degree of organ impairment. Respiratory tract represents major site of damage, with lung interstitium, pleura, pulmonary vasculature and airways possibly affected. In systemic sclerodermia and rheumatoid arthritis, lung disease is the most significant cause of morbidity and mortality. Breathing difficulties may either present as first symptoms of underlying rheumatoid disease or may appear at any time during the course of the disease. Rheumatologists should routinely screen their patients for possible lung impairment. Similarly, extrapulmonal signs should be assessed by pulmonologists in patients referred for dyspnea. Currently, novel antifibrotic therapy is available not only for patients with idiopathic pulmonary fibrosis (IPF), but also for selected group of patients with non-IPF progressive fenotype associated interstitial lung disease having solid evidence-based background. Interdisciplinary approach in terms of collaboration between pulmonologist and rheumatologist is of key importance as proper identification of possible candidates and early onset of therapy is crucial.

Keywords:

interstitial lung disease – nintedanib – systemic rheumatic diseases – INBUILD – INPULSIS

Zdroje

1. Cottin V, Hirani NA, Hotchkin DL et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018; 27(150). doi: 10.1183/16000617.0076–2018.

2. Steele R, Hudson M, Lo E, Baron M. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken). 2012; 64(4): 519– 524. doi: 10.1002/ACR.21583

3. Sanchéz-Cano D, Ortego-Centeno N, Callejas JL et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int. 2018; 38(3): 363–374. doi: 10.1007/S00296–017–3916-X.

4. Bongartz T, Nannini C, Medina-Velasques YF et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010; 62(6): 1583–1591. doi: 10.1002/ART.27405.

5. Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10): 1809–1815. doi: 10.1136/ARD.2009.114264.

6. Tran T, Šterzlová M, Mogulkoc N et al. The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respir Res. 2020; 21(1). doi: 10.1186/S12931–019–1271-Z.

7. Doubková M, Švancara J, Svoboda M et al. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Respir J. 2018; 12(4): 1526–1535. doi: 10.1111/CRJ.12700.

8. Fukihara J, Kondoh Y. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016; 10(12): 1247–1254. doi: 10.1080/17476348.2016.1249854.

9. Richeldi L, Kolb M, Jouneau S et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020; 20(1). doi: 10.1186/S12890–019–1030–4.

10. Wuyts WA, Papiris S, Manalie et al. The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach. Adv Ther. 2020; 37(7): 3246–3264. doi: 10.1007/S12325–020–01384–0.

11. Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res 2019 201. 2019; 20(1): 1–8. doi: 10.1186/S12931–019–1022–1.

12. Distler O, Highland KB, Gahlemann M et al. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. https://doi.org/101056/NEJMoa1903076. 2019; 380(26): 2518– 2528. doi: 10.1056/NEJMOA1903076.

13. Flaherty KR, Wells AU, Cottin V et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. https://doi.org/101056/NEJMoa1908681. 2019; 381(18): 1718–1727. doi: 10.1056/NEJMOA1908681.

14. Brown KK, Martinez FJ, Walsh SLF et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020; 55(6). doi: 10.1183/13993003.00085– 2020

15. Doubková M. Intersticiální plicní postižení a systémová onemocnění pojiva – doporučení diagnostiky a léčby. Aktualizace 2021. Dostupné online http://www.pneumologie. cz/upload/1612897353.6323.doc